Boult Wade Tennant
Bulletins » New referral to the Enlarged Board of Appeal on claim interpretation

A European Patent Office (EPO) Board of Appeal has recently referred three questions to the Enlarged Board of Appeal to seek clarity in interpreting the terms of a claim.

Contrasting approaches to claim interpretation have evolved at the EPO.  At one extreme, terms in claims are interpreted in isolation, without any recourse to the description.  At the other extreme, the patent application is able to act as its own dictionary such that the description can provide definitions for claim terms that are contrary to their normal meaning. Thus, a term in a claim that is otherwise clear may be given a broader or narrower interpretation.  There is also the middle ground where terms appearing in the claims that are clear are given their normal meanings and the description ignored, but the description is used to remove any ambiguity regarding claim terms. These different approaches are reflected across a wide body of case law.

Another consideration is Article 69 of the European Patent Convention (EPC) that says the extent of protection of a granted European patent is determined by the claims, and that the description and drawings shall be used to interpret the claims. However, case law diverges on the question of whether Article 69 should also apply when considering patentability during examination and opposition proceedings, for example when determining novelty and inventive step.

The appeal case leading to the new referral, T 0439/22, has claims that contain the term “gathered sheet” which is used to describe a tobacco sheet in an aerosol generating device.  The Board took the view that “gathered sheet” was a well-known term in the technical field with an accepted meaning, but the description of the patent specification set out further definitions that were broader. So, is this a case were the description can act as its own dictionary such that the broader meaning should be given to the term “gathered sheet” when interpreting the claims?

The Board of Appeal has referred the following three questions to the Enlarged Board of Appeal, as case G 1/24, in order to clarify situations like those described above:

  1. Is Article 69(1), second sentence EPC and Article 1 of the Protocol on the Interpretation of Article 69 EPC to be applied on the interpretation of patent claims when assessing the patentability of an invention under Articles 52 to 57 EPC?
  2. May the description and figures be consulted when interpreting the claims to assess patentability and, if so, may this be done generally or only if the person skilled in the art finds a claim to be unclear or ambiguous when read in isolation?
  3. May a definition or similar information on a term used in the claims which is explicitly given in the description be disregarded when interpreting the claims to assess patentability and, if so, under what conditions?

Before the referral can be considered, it must first be deemed admissible by the Enlarged Board of Appeal.  Even if admitted, the Enlarged Board of Appeal may narrow the questions if they are considered broader than justified. So, it will be interesting to see how this appeal progresses over the coming months.  The EPO have issued a notice to say that, while G 1/24 remans pending, proceedings before the examination and opposition divisions will continue.

For the time being at least, good patent practice remains unchanged.  Wherever possible, reliance on the description to impart a particular meaning to a claim term should be avoided: it is far better for the claims to be able to stand on their own.  Where flexibility is required, for example to provide room to manoeuvre around prior art, alternative claim formulations should be included to provide explicit basis for later amendment of the claims.  Trying to force a broader than normal meaning onto a claim term is more risky because, if not corrected before grant, the opportunity to do so after grant may be prevented by the restriction on post-grant amendments that widen the scope of protection. So an Opposition Division or Board of Appeal may interpret a claim term narrowly, and then refuse any attempt to amend the claim to achieve a broader meaning.

Any questions can be directed to your usual contact at Boult Wade Tennant.

Relevant sectors
Aerospace
  • Commercial aviation
  • Defence and security
  • Space and satellites
  • Unmanned aerial vehicles
Artificial Intelligence and Machine Learning
Automotive
  • Autonomous vehicles
  • Electric vehicles
  • Engines
Biotechnology
  • Antibody engineering
  • Antibody manufacture and formulation
  • Bioinformatics
  • Biosimilars
  • Drug delivery
  • Gene editing (e.g. CRISPR)
  • Genomic and molecular tools and methods
  • GM crops
  • Immuno-oncology (e.g. checkpoint inhibitors; modified T cells)
  • Next generation sequencing
  • Nucleic acid synthesis
  • Personalised medicine/disease biomarkers
  • Recombinant protein production and purification
  • Stem cell therapies
  • Supplementary protection certificates (SPCs)
  • Synthetic biology
  • Therapeutic antibodies
  • Vaccinology (e.g. viral vectors; mRNA vaccines)
  • Women’s health products
Chemicals
  • Agrochemicals
  • Catalysts
  • Dispersions and colloids
  • Lubricants
  • Polymers and plastics
Communications and Networks
  • Cloud computing
  • Internet of things (IOT)
  • Oceanography, marine
  • Wired and wireless networks
Computing and Software
  • Artificial intelligence and machine learning
  • Bioinformatics
  • Blockchain and distributed ledgers
  • Communications and networks
  • Computer games
  • Data and software security, cryptography and digital rights management (DRM)
  • Data management and storage, databases and data compression
  • Digital assistants, virtual assistants and software agents
  • Fintech and adtech
  • Machine vision
  • Metaverse, virtual reality (VR) and augmented reality (AR)
  • Motor capture
  • Multimedia, audio/video processing and animation
  • Natural language processing
  • Quantum computing
  • Robotic process automation
  • Search engines
  • Signal processing
  • Software applications and systems, mobile applications, user interfaces
Consumer Goods and Retail
  • Anti-counterfeit devices
  • Beauty
  • Fashion
  • Health, fitness and sport
  • Household goods
  • Luxury goods
  • Moda
  • Retail
Electronics and Electrical Devices
  • Computer and IT architecture and system design
  • Medical devices
  • Optics
  • Restaurants and bars
  • Robotics
  • Scientific instruments
  • Semiconductor devices
  • Testing systems, control systems, signal processing
  • Travel and leisure
  • Wearable tech and human interfaces
Energy and Green Technologies
  • Biofuels
  • Clean air
  • Fuel cells and battery technology
  • Renewables and recycling
  • Solar power
  • Water, oil and gas, nuclear, fusion, fission
  • Wind turbines
Food and Beverage
  • Beverages
  • Nutrition
  • Retail
Industrial Manufacturing and Processing
  • Packaging
  • Polymers and plastics
  • Printing tech
  • Additive manufacturing
  • Coatings
  • Construction
Materials
  • Advanced materials
  • Composite materials
  • Metallurgy and alloys
  • Nanotechnology
Medical Devices and Diagnostics
  • Artificial intelligence
  • Devices
  • Diagnostic instruments
  • Digital health
  • Drug delivery
  • Immuno-oncology
  • In vitro diagnostics
  • Medtech
Pharmaceuticals
  • Diagnostics
  • Drug delivery
  • Generic market entry
  • Medicinal chemistry
  • Methods of production and synthesis
  • Personalised medicine/disease biomarkers
  • Pharmaceutical formulations
  • Pharmaceuticalsceutical formulations
  • Polymorphs
  • Small molecule pharmaceuticals
  • Supplementary protection certificates (SPCs)
Trade Marks
  • Consumer goods
  • Cosmetics and perfumery
  • Financial services
  • Mechanical engineering
  • Mechanical products
  • Services
  • Telecommunications
Relevant sectors